Concordance between 18F-RAD101 Pet and contrast-enhanced MRI 93.5 patient-level agreement preliminary sensitivity of 85.7 against the reference standard Favourable safety profile with no serious treatment-emergent advers
Why Is Radiopharm Theranostics Limited (RADX) Stock Down Today?
Updated Nov 22, 2026 5:31 AM ET ยท Prev Close $0.67
Session Regime & Catalyst Assessment
68% Signal ConvictionRadiopharm Theranostics Limited Pulling Back 6.33% on 0.28x Relative Volume
Radiopharm Theranostics Limited (RADX) is pulling back 6.33% (-$0.04) to $0.63 on 0.28x average session volume. Relative to benchmarks, RADX is lagging the S&P 500 by -2.69%. 14-day RSI stands at 26.9, keeping momentum in a oversold regime.
Concordance between 18F-RAD101 Pet and contrast-enhanced MRI 93.5 patient-level agreement preliminary sensitivity of 85.7 against the reference standard Favourable safety profile with no serious treatment-emergent advers
Price ($0.63) trades relative to 20-day SMA ($0.86) and 50-day SMA ($1.15).
Market & Sector Relative Strength
RADX lagging the S&P 500 by -2.69%Options Flow & Execution Desk
Recent RADX Catalyst Headlines
Verified WireSingle, multicenter Phase 3 imaging trial of approximately 280 patients with brain metastases designed to demonstrate sensitivity and specificity above prespecified performance thresholds Radiopharm Theranostics advancin
Phase 3 imaging trial of RAD101 in recurrent brain metastases from solid tumors expected to initiate in 1Q27 following successful end-of-phase 2 meeting with U.S. Food and Drug Administration Reported positive Phase 1 im
Constructive FDA interaction provides clear framework for RAD101 pivotal clinical development plan in brain metastases imaging Currently executing Phase 3 readiness activities in anticipation of FDA meeting minutes in ne
1โ3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $0.63 (session support) for directional breakout confirmation.
Technical Regime (RADX)
BEARISH MA TRENDAbout Radiopharm Theranostics Limited
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.
Get Instant RADX Catalyst Alerts
Receive an email alert when RADX triggers an unusual volume breakout, options sweep, or rating shift.
RADX Session & Catalyst FAQ
Why is RADX stock down today?
Radiopharm Theranostics Limited (RADX) is pulling back 6.33% (-$0.04) to $0.63 on 0.28x average session volume. Relative to benchmarks, RADX is lagging the S&P 500 by -2.69%. 14-day RSI stands at 26.9, keeping momentum in a oversold regime.
Is RADX stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.28x relative volume (low participation). Our multi-factor model currently rates RADX as HOLD. Review full valuation, quality, and timing signals on the RADX Buy or Sell Decision Brief โ
What is RADX's intrinsic value and expected trading range?
At $0.63, RADX's modeled 1-to-3 session range is $0.60 โ $0.66, with a key inflection level at $0.63 (session support). Compare current price against multi-year cash flow projections in the RADX Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for RADX?
RSI at 26.9 indicates oversold conditions โ watch for mean-reversion support. RADX trades at $0.63 relative to its 20-day SMA ($0.86) and 50-day SMA ($1.15), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.